BI Asset Management Fondsmaeglerselskab A S Raises Stake in Becton, Dickinson and Company $BDX

Key Points

• BI Asset Management Fondsmaeglerselskab A S increased its holdings in Becton, Dickinson and Company by 96.7%, acquiring 16,568 shares during the first quarter.
• Becton, Dickinson reported a quarterly earnings per share (EPS) of $3.68, surpassing analysts' expectations of $3.40, with a year-over-year revenue increase of 10.4%.
• The company declared a quarterly dividend of $1.04, which provides a dividend yield of 2.1%, payable at the end of September.

BI Asset Management Fondsmaeglerselskab A S boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 96.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,694 shares of the medical instruments supplier's stock after purchasing an additional 16,568 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Becton, Dickinson and Company were worth $7,718,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BDX. Smallwood Wealth Investment Management LLC purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth $27,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares during the period. Finally, Nexus Investment Management ULC purchased a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $34,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 1.5%

BDX traded up $2.8730 during trading hours on Friday, hitting $199.5030. 1,619,788 shares of the company's stock were exchanged, compared to its average volume of 2,720,196. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm has a 50 day moving average of $180.65 and a 200 day moving average of $195.60. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market cap of $57.18 billion, a P/E ratio of 35.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the prior year, the firm posted $3.50 EPS. The company's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Shan sold 1,166 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,214 shares of company stock worth $579,206 in the last 90 days. Company insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BDX. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a report on Friday, May 2nd. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Piper Sandler reissued a "neutral" rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.